![UCB News в Twitter: "Traditionally, science is connected to the patient. We want to connect patients to science. This is the business model of today and tomorrow”. Jean-Christophe Tellier, CEO at UCB # UCB News в Twitter: "Traditionally, science is connected to the patient. We want to connect patients to science. This is the business model of today and tomorrow”. Jean-Christophe Tellier, CEO at UCB #](https://pbs.twimg.com/media/DxhymlLWkAEaTZr.jpg)
UCB News в Twitter: "Traditionally, science is connected to the patient. We want to connect patients to science. This is the business model of today and tomorrow”. Jean-Christophe Tellier, CEO at UCB #
![European Patients' Forum on Twitter: ""Live the life that you want, not the one that is dictated by disease. But nobody can solve this individually. We should co-construct solutions" - some wise European Patients' Forum on Twitter: ""Live the life that you want, not the one that is dictated by disease. But nobody can solve this individually. We should co-construct solutions" - some wise](https://pbs.twimg.com/media/EJLugNuW4AAbLQs.jpg)
European Patients' Forum on Twitter: ""Live the life that you want, not the one that is dictated by disease. But nobody can solve this individually. We should co-construct solutions" - some wise
![IFPMA on Twitter: "We are pleased to welcome Jean-Christophe Tellier, CEO @ucb_news, as the new IFPMA president. More information: https://t.co/vZufI0SjIX https://t.co/t52isUOGUT" / Twitter IFPMA on Twitter: "We are pleased to welcome Jean-Christophe Tellier, CEO @ucb_news, as the new IFPMA president. More information: https://t.co/vZufI0SjIX https://t.co/t52isUOGUT" / Twitter](https://pbs.twimg.com/media/EslA7nUXIAEkBJJ.jpg)
IFPMA on Twitter: "We are pleased to welcome Jean-Christophe Tellier, CEO @ucb_news, as the new IFPMA president. More information: https://t.co/vZufI0SjIX https://t.co/t52isUOGUT" / Twitter
Jean-Christophe Tellier (UCB) : « UCB a fait les bons choix pour assurer sa croissance " - Vidéo Dailymotion
![UCB's bimekizumab blows J&J's Stelara away in phase 3, raising expectations for Cosentyx showdown | FierceBiotech UCB's bimekizumab blows J&J's Stelara away in phase 3, raising expectations for Cosentyx showdown | FierceBiotech](https://qtxasset.com/fiercebiotech/1592222342/2_3_5a_tellier.jpg/2_3_5a_tellier.jpg?VersionId=Ata2PJYobzKykSAeUHxduHtQl60.0fjp)
UCB's bimekizumab blows J&J's Stelara away in phase 3, raising expectations for Cosentyx showdown | FierceBiotech
![Jean-Christophe Tellier: «La Suisse est par nature très accueillante pour l'industrie pharmaceutique» - Le Temps Jean-Christophe Tellier: «La Suisse est par nature très accueillante pour l'industrie pharmaceutique» - Le Temps](https://assets.letemps.ch/sites/default/files/styles/original/public/media/2021/09/09/file7hgndxa6rtl18o4h4b1u.jpg?itok=Is3e0vHp)
Jean-Christophe Tellier: «La Suisse est par nature très accueillante pour l'industrie pharmaceutique» - Le Temps
![Jean-Christophe Tellier est le mieux payé parmi les patrons des entreprises du Bel 20: le CEO d'UCB a touché 5,23 millions d'euros en 2018 Jean-Christophe Tellier est le mieux payé parmi les patrons des entreprises du Bel 20: le CEO d'UCB a touché 5,23 millions d'euros en 2018](https://www.sudinfo.be/sites/default/files/dpistyles_v2/ena_16_9_extra_big/2019/04/06/node_111784/34220042/public/2019/04/06/B9719167596Z.1_20190406130146_000+GPPDB9UDF.1-0.jpg?itok=d-VB1dUv1554548565)
Jean-Christophe Tellier est le mieux payé parmi les patrons des entreprises du Bel 20: le CEO d'UCB a touché 5,23 millions d'euros en 2018
![Jean-Christophe Tellier (UCB): "Je suis assez sceptique sur le fait d'avoir une crise et puis de revenir à la normale" - La Libre Jean-Christophe Tellier (UCB): "Je suis assez sceptique sur le fait d'avoir une crise et puis de revenir à la normale" - La Libre](https://www.lalibre.be/resizer/miwt1WFGrSLGBCdt9GivuqkCOVc=/1200x630/filters:quality(70):format(jpg):focal(2495x1671.5:2505x1661.5):watermark(cloudfront-eu-central-1.images.arcpublishing.com/ipmgroup/EF665FJJCNGHFFHRRMWR57UKMI.png,0,30,0)/cloudfront-eu-central-1.images.arcpublishing.com/ipmgroup/LBOJYSNZ55HCFJVUPJDBVA5QJA.jpg)